Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for CLDN1+ tumors, leveraging the unique role of CLDN1 in cancer and fibrotic disease. The company is pioneering the use of anti-CLDN1 antibody-drug conjugates (ADCs), specifically its first-in-class assets ALE.P02 and ALE.P03. Recently, the FDA cleared the IND application for ALE.P02, allowing it to advance into a Phase 1/2 clinical trial for patients with advanced or metastatic CLDN1+ squamous solid tumors. Alentis was founded on pioneering research at the University of Strasbourg and Inserm.

Learn more at www.alentis.ch